Jennifer Diamond
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Triple Negative Breast Neoplasms | 16 | 2024 | 188 | 6.700 |
Why?
| Breast Neoplasms | 23 | 2023 | 2139 | 4.390 |
Why?
| Immunoconjugates | 7 | 2023 | 101 | 2.620 |
Why?
| Antineoplastic Agents | 23 | 2023 | 2078 | 2.590 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 1579 | 2.460 |
Why?
| Pyrimidines | 9 | 2021 | 448 | 2.400 |
Why?
| Receptor, ErbB-2 | 11 | 2023 | 337 | 1.940 |
Why?
| Protein Kinase Inhibitors | 10 | 2022 | 883 | 1.730 |
Why?
| Piperazines | 4 | 2020 | 334 | 1.700 |
Why?
| Paclitaxel | 6 | 2022 | 216 | 1.620 |
Why?
| Camptothecin | 9 | 2023 | 107 | 1.610 |
Why?
| Neoplasms | 14 | 2022 | 2467 | 1.600 |
Why?
| Pyrazoles | 6 | 2021 | 406 | 1.400 |
Why?
| Quinoxalines | 2 | 2020 | 65 | 1.320 |
Why?
| Antibodies, Monoclonal, Humanized | 10 | 2024 | 763 | 1.290 |
Why?
| Azepines | 3 | 2020 | 89 | 1.250 |
Why?
| Ovarian Neoplasms | 4 | 2020 | 488 | 1.220 |
Why?
| Histone Deacetylase Inhibitors | 4 | 2024 | 207 | 1.210 |
Why?
| Cyclin-Dependent Kinase 4 | 2 | 2018 | 42 | 1.110 |
Why?
| Cyclin-Dependent Kinase 6 | 2 | 2018 | 39 | 1.100 |
Why?
| Neutropenia | 4 | 2022 | 135 | 0.890 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1341 | 0.790 |
Why?
| Xenograft Model Antitumor Assays | 11 | 2021 | 815 | 0.760 |
Why?
| beta Catenin | 2 | 2020 | 223 | 0.760 |
Why?
| Breast Neoplasms, Male | 2 | 2018 | 29 | 0.740 |
Why?
| Female | 49 | 2024 | 68842 | 0.700 |
Why?
| Cancer Care Facilities | 1 | 2020 | 31 | 0.700 |
Why?
| Chemotherapy, Adjuvant | 4 | 2023 | 383 | 0.690 |
Why?
| Maximum Tolerated Dose | 9 | 2022 | 196 | 0.690 |
Why?
| Benzoxazoles | 1 | 2020 | 20 | 0.690 |
Why?
| Receptors, Estrogen | 3 | 2021 | 429 | 0.680 |
Why?
| Carcinoma, Lobular | 2 | 2018 | 48 | 0.680 |
Why?
| eIF-2 Kinase | 1 | 2019 | 30 | 0.650 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 209 | 0.640 |
Why?
| Tumor Microenvironment | 4 | 2024 | 616 | 0.640 |
Why?
| Anthracyclines | 3 | 2023 | 46 | 0.610 |
Why?
| Humans | 62 | 2024 | 130305 | 0.600 |
Why?
| Taxoids | 3 | 2023 | 98 | 0.600 |
Why?
| Drug Resistance, Neoplasm | 4 | 2020 | 755 | 0.580 |
Why?
| Wnt Signaling Pathway | 1 | 2019 | 169 | 0.580 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2018 | 82 | 0.570 |
Why?
| Aurora Kinase A | 4 | 2020 | 55 | 0.570 |
Why?
| Trastuzumab | 4 | 2023 | 100 | 0.560 |
Why?
| Aged | 22 | 2023 | 22282 | 0.560 |
Why?
| Pyrazines | 2 | 2018 | 89 | 0.540 |
Why?
| Colonic Neoplasms | 1 | 2018 | 237 | 0.520 |
Why?
| Myocardial Infarction | 1 | 2023 | 1036 | 0.520 |
Why?
| Pyridines | 2 | 2018 | 474 | 0.510 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2024 | 513 | 0.500 |
Why?
| Neoadjuvant Therapy | 1 | 2018 | 387 | 0.490 |
Why?
| Nuclear Proteins | 2 | 2023 | 652 | 0.490 |
Why?
| Angiopoietin-1 | 1 | 2015 | 11 | 0.490 |
Why?
| Angiopoietin-2 | 1 | 2015 | 15 | 0.490 |
Why?
| Uterine Cervical Neoplasms | 1 | 2017 | 234 | 0.450 |
Why?
| Medicare | 4 | 2023 | 740 | 0.440 |
Why?
| Cell Line, Tumor | 9 | 2022 | 3185 | 0.440 |
Why?
| Colorectal Neoplasms | 5 | 2022 | 733 | 0.430 |
Why?
| Middle Aged | 23 | 2021 | 31322 | 0.420 |
Why?
| Antibodies, Monoclonal | 4 | 2024 | 1372 | 0.410 |
Why?
| Dose-Response Relationship, Drug | 6 | 2022 | 1983 | 0.410 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 315 | 0.400 |
Why?
| Cell Proliferation | 8 | 2020 | 2381 | 0.400 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2013 | 75 | 0.400 |
Why?
| Antineoplastic Agents, Immunological | 3 | 2019 | 174 | 0.400 |
Why?
| Recombinant Fusion Proteins | 1 | 2015 | 645 | 0.390 |
Why?
| Point Mutation | 1 | 2013 | 227 | 0.390 |
Why?
| Adult | 24 | 2024 | 35711 | 0.390 |
Why?
| Treatment Outcome | 12 | 2022 | 10341 | 0.380 |
Why?
| Triazoles | 1 | 2013 | 155 | 0.380 |
Why?
| Angiogenesis Inhibitors | 3 | 2018 | 223 | 0.370 |
Why?
| Mice, Nude | 6 | 2020 | 688 | 0.360 |
Why?
| Carcinoma, Renal Cell | 1 | 2013 | 181 | 0.360 |
Why?
| Mitochondria | 1 | 2017 | 857 | 0.350 |
Why?
| Clinical Trials, Phase I as Topic | 2 | 2020 | 50 | 0.350 |
Why?
| Neoplasm Recurrence, Local | 4 | 2021 | 959 | 0.340 |
Why?
| Histones | 3 | 2023 | 589 | 0.340 |
Why?
| Heart Failure | 1 | 2023 | 2164 | 0.340 |
Why?
| Neoplasm Metastasis | 4 | 2020 | 615 | 0.340 |
Why?
| Genes, BRCA2 | 1 | 2009 | 24 | 0.340 |
Why?
| Genes, BRCA1 | 1 | 2009 | 32 | 0.330 |
Why?
| Biomarkers, Tumor | 2 | 2014 | 1196 | 0.330 |
Why?
| BRCA2 Protein | 1 | 2009 | 53 | 0.320 |
Why?
| Molecular Targeted Therapy | 3 | 2019 | 389 | 0.320 |
Why?
| Aged, 80 and over | 8 | 2020 | 7128 | 0.320 |
Why?
| Thrombophilia | 1 | 2009 | 68 | 0.320 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2009 | 52 | 0.310 |
Why?
| Neoplasm Staging | 5 | 2021 | 1294 | 0.310 |
Why?
| Lung Neoplasms | 2 | 2024 | 2376 | 0.310 |
Why?
| Kidney Neoplasms | 1 | 2013 | 352 | 0.310 |
Why?
| Quinolines | 2 | 2021 | 149 | 0.300 |
Why?
| Apoptosis | 7 | 2024 | 2519 | 0.300 |
Why?
| Aromatase Inhibitors | 2 | 2018 | 52 | 0.300 |
Why?
| Receptors, Progesterone | 2 | 2021 | 345 | 0.290 |
Why?
| DNA-Binding Proteins | 1 | 2015 | 1433 | 0.280 |
Why?
| Mice | 9 | 2021 | 16832 | 0.270 |
Why?
| Models, Biological | 1 | 2014 | 1716 | 0.260 |
Why?
| Doxorubicin | 3 | 2024 | 321 | 0.250 |
Why?
| Liver Neoplasms | 1 | 2009 | 643 | 0.220 |
Why?
| Cyclophosphamide | 2 | 2018 | 232 | 0.220 |
Why?
| Radiosurgery | 2 | 2019 | 316 | 0.220 |
Why?
| Disease Models, Animal | 3 | 2021 | 4044 | 0.210 |
Why?
| United States | 5 | 2023 | 14110 | 0.210 |
Why?
| Animals | 11 | 2021 | 35076 | 0.200 |
Why?
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 10 | 0.200 |
Why?
| Biopsy | 2 | 2018 | 1107 | 0.200 |
Why?
| Histone Deacetylase 1 | 1 | 2022 | 22 | 0.200 |
Why?
| Aurora Kinases | 2 | 2012 | 29 | 0.190 |
Why?
| Administration, Oral | 3 | 2022 | 788 | 0.190 |
Why?
| G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 46 | 0.190 |
Why?
| Disease Progression | 4 | 2019 | 2639 | 0.190 |
Why?
| Topoisomerase I Inhibitors | 2 | 2022 | 17 | 0.190 |
Why?
| Fluorouracil | 1 | 2022 | 201 | 0.190 |
Why?
| Acetylation | 1 | 2022 | 237 | 0.180 |
Why?
| Biliary Tract Neoplasms | 1 | 2021 | 25 | 0.180 |
Why?
| Arrhythmias, Cardiac | 1 | 2023 | 318 | 0.180 |
Why?
| Androstadienes | 1 | 2021 | 107 | 0.180 |
Why?
| Diarrhea | 2 | 2019 | 179 | 0.180 |
Why?
| Carboplatin | 1 | 2021 | 140 | 0.180 |
Why?
| Heterografts | 1 | 2021 | 129 | 0.180 |
Why?
| Necrosis | 2 | 2019 | 236 | 0.170 |
Why?
| Hospitals, University | 1 | 2021 | 177 | 0.170 |
Why?
| Drug Administration Schedule | 3 | 2017 | 766 | 0.170 |
Why?
| Fatigue | 2 | 2022 | 322 | 0.170 |
Why?
| Histone Deacetylases | 1 | 2022 | 211 | 0.170 |
Why?
| Immunotherapy | 2 | 2023 | 599 | 0.170 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 59 | 0.170 |
Why?
| Male | 13 | 2021 | 63748 | 0.170 |
Why?
| Clinical Trials as Topic | 3 | 2016 | 1015 | 0.170 |
Why?
| Benzodiazepines | 1 | 2021 | 133 | 0.170 |
Why?
| Immune System | 1 | 2021 | 176 | 0.160 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 116 | 0.160 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 43 | 0.160 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 869 | 0.160 |
Why?
| Tumor Cells, Cultured | 1 | 2020 | 937 | 0.150 |
Why?
| Albumins | 1 | 2019 | 103 | 0.150 |
Why?
| Maintenance Chemotherapy | 1 | 2018 | 22 | 0.150 |
Why?
| Aquaporin 4 | 1 | 2019 | 95 | 0.150 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2018 | 533 | 0.150 |
Why?
| Aminopyridines | 1 | 2018 | 96 | 0.150 |
Why?
| Nausea | 1 | 2018 | 109 | 0.150 |
Why?
| Antibodies, Bispecific | 1 | 2018 | 49 | 0.150 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 1245 | 0.140 |
Why?
| Breast | 1 | 2018 | 152 | 0.140 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 1028 | 0.140 |
Why?
| Radiotherapy, Adjuvant | 1 | 2018 | 213 | 0.140 |
Why?
| Purines | 1 | 2018 | 170 | 0.140 |
Why?
| Mastectomy | 1 | 2018 | 130 | 0.140 |
Why?
| Benzimidazoles | 1 | 2018 | 160 | 0.140 |
Why?
| Topotecan | 1 | 2017 | 12 | 0.140 |
Why?
| Isoflavones | 1 | 2017 | 25 | 0.140 |
Why?
| Imidazoles | 1 | 2018 | 231 | 0.140 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 215 | 0.140 |
Why?
| Survival Analysis | 1 | 2020 | 1293 | 0.140 |
Why?
| Carbolines | 1 | 2017 | 27 | 0.140 |
Why?
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 19 | 0.140 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 227 | 0.140 |
Why?
| Inhibitory Concentration 50 | 2 | 2016 | 83 | 0.130 |
Why?
| Nanoparticles | 1 | 2021 | 370 | 0.130 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2016 | 71 | 0.130 |
Why?
| Cell Survival | 1 | 2019 | 1098 | 0.130 |
Why?
| Insulin-Like Growth Factor I | 1 | 2018 | 308 | 0.130 |
Why?
| Hypertension | 2 | 2018 | 1245 | 0.130 |
Why?
| GPI-Linked Proteins | 1 | 2016 | 67 | 0.130 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 398 | 0.120 |
Why?
| Neoplasms, Second Primary | 1 | 2016 | 109 | 0.120 |
Why?
| Tumor Protein p73 | 1 | 2015 | 14 | 0.120 |
Why?
| Antibodies, Neoplasm | 1 | 2015 | 35 | 0.120 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1069 | 0.120 |
Why?
| Phosphorylation | 1 | 2019 | 1709 | 0.120 |
Why?
| Hodgkin Disease | 1 | 2016 | 136 | 0.120 |
Why?
| Risk Reduction Behavior | 1 | 2016 | 212 | 0.120 |
Why?
| Retrospective Studies | 3 | 2021 | 14675 | 0.120 |
Why?
| Maytansine | 1 | 2014 | 16 | 0.110 |
Why?
| Demography | 1 | 2015 | 281 | 0.110 |
Why?
| Brain Edema | 1 | 2014 | 61 | 0.110 |
Why?
| Drug Interactions | 1 | 2015 | 370 | 0.110 |
Why?
| Protein Kinases | 1 | 2015 | 307 | 0.110 |
Why?
| Survival Rate | 2 | 2019 | 1904 | 0.110 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1381 | 0.110 |
Why?
| Threonine | 1 | 2013 | 44 | 0.110 |
Why?
| Sulfones | 1 | 2014 | 109 | 0.110 |
Why?
| Glycine | 1 | 2014 | 166 | 0.100 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 174 | 0.100 |
Why?
| Tumor Stem Cell Assay | 1 | 2012 | 32 | 0.100 |
Why?
| Analgesics, Opioid | 1 | 2021 | 921 | 0.100 |
Why?
| Time Factors | 2 | 2020 | 6615 | 0.100 |
Why?
| Drug Design | 1 | 2013 | 157 | 0.100 |
Why?
| Methionine | 1 | 2013 | 159 | 0.100 |
Why?
| Heterozygote | 1 | 2013 | 270 | 0.100 |
Why?
| Disease-Free Survival | 1 | 2014 | 658 | 0.100 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2013 | 323 | 0.100 |
Why?
| Treatment Failure | 1 | 2013 | 351 | 0.100 |
Why?
| Neovascularization, Pathologic | 1 | 2013 | 302 | 0.090 |
Why?
| Computational Biology | 1 | 2015 | 600 | 0.090 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 328 | 0.090 |
Why?
| Cluster Analysis | 1 | 2012 | 485 | 0.090 |
Why?
| Carcinoma in Situ | 1 | 2011 | 45 | 0.090 |
Why?
| Cellular Senescence | 1 | 2012 | 177 | 0.090 |
Why?
| Risk Assessment | 1 | 2020 | 3310 | 0.090 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 237 | 0.090 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 86 | 0.090 |
Why?
| Colorado | 1 | 2020 | 4471 | 0.090 |
Why?
| Mutation | 2 | 2012 | 3723 | 0.080 |
Why?
| Sequence Analysis, DNA | 1 | 2013 | 780 | 0.080 |
Why?
| Brain Neoplasms | 2 | 2019 | 1149 | 0.080 |
Why?
| Tumor Burden | 1 | 2010 | 285 | 0.080 |
Why?
| Pregnancy Trimester, Second | 1 | 2009 | 76 | 0.080 |
Why?
| Keratinocytes | 1 | 2010 | 244 | 0.080 |
Why?
| Mastectomy, Segmental | 1 | 2009 | 85 | 0.080 |
Why?
| Pregnancy Trimester, First | 1 | 2009 | 135 | 0.080 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 90 | 0.080 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2009 | 183 | 0.080 |
Why?
| Lymph Node Excision | 1 | 2009 | 168 | 0.070 |
Why?
| Infusions, Intravenous | 2 | 2019 | 395 | 0.070 |
Why?
| Risk | 1 | 2009 | 873 | 0.070 |
Why?
| Cell Adhesion Molecules | 2 | 2019 | 177 | 0.070 |
Why?
| Risk Factors | 1 | 2020 | 9865 | 0.070 |
Why?
| Prognosis | 2 | 2018 | 3830 | 0.070 |
Why?
| Gene Expression Profiling | 1 | 2012 | 1714 | 0.060 |
Why?
| Cell Cycle Proteins | 2 | 2023 | 585 | 0.060 |
Why?
| Antigens, Neoplasm | 2 | 2019 | 311 | 0.060 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2023 | 842 | 0.060 |
Why?
| Cell Cycle | 2 | 2018 | 587 | 0.060 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1219 | 0.050 |
Why?
| Mesylates | 1 | 2022 | 7 | 0.050 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 65 | 0.050 |
Why?
| Signal Transduction | 2 | 2014 | 4930 | 0.050 |
Why?
| Clinical Protocols | 1 | 2023 | 258 | 0.050 |
Why?
| Ligands | 1 | 2024 | 624 | 0.050 |
Why?
| RNA, Small Interfering | 1 | 2024 | 586 | 0.050 |
Why?
| Chimerism | 1 | 2021 | 29 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2021 | 68 | 0.040 |
Why?
| Lymphocyte Subsets | 1 | 2021 | 86 | 0.040 |
Why?
| Liver | 1 | 2009 | 1846 | 0.040 |
Why?
| Mice, SCID | 1 | 2021 | 349 | 0.040 |
Why?
| SEER Program | 1 | 2021 | 208 | 0.040 |
Why?
| Hormones | 1 | 2020 | 140 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 586 | 0.040 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| Tissue Distribution | 1 | 2018 | 297 | 0.040 |
Why?
| Infant, Newborn | 1 | 2009 | 5741 | 0.040 |
Why?
| Anemia | 1 | 2019 | 156 | 0.040 |
Why?
| Pregnancy | 1 | 2009 | 6301 | 0.030 |
Why?
| Cetuximab | 1 | 2016 | 94 | 0.030 |
Why?
| Retreatment | 1 | 2016 | 69 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 116 | 0.030 |
Why?
| Neoplasm Transplantation | 1 | 2016 | 259 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 197 | 0.030 |
Why?
| Platinum | 1 | 2016 | 44 | 0.030 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 578 | 0.030 |
Why?
| History, Ancient | 1 | 2015 | 52 | 0.030 |
Why?
| Transcription Factors | 1 | 2023 | 1649 | 0.030 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 265 | 0.030 |
Why?
| Databases, Genetic | 1 | 2015 | 229 | 0.030 |
Why?
| DNA Damage | 1 | 2017 | 379 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2811 | 0.030 |
Why?
| Biomarkers | 2 | 2016 | 3923 | 0.030 |
Why?
| Opioid-Related Disorders | 1 | 2021 | 506 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 3084 | 0.020 |
Why?
| Drug Combinations | 1 | 2013 | 328 | 0.020 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 260 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 431 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2016 | 1711 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2011 | 192 | 0.020 |
Why?
| Cohort Studies | 1 | 2021 | 5431 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2017 | 1415 | 0.020 |
Why?
| HT29 Cells | 1 | 2010 | 36 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2014 | 832 | 0.020 |
Why?
| Proto-Oncogene Proteins | 1 | 2014 | 645 | 0.020 |
Why?
| Protein-Tyrosine Kinases | 1 | 2013 | 429 | 0.020 |
Why?
| ErbB Receptors | 1 | 2013 | 611 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2010 | 109 | 0.020 |
Why?
| Capillary Permeability | 1 | 2010 | 141 | 0.020 |
Why?
| Patient Selection | 1 | 2013 | 678 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2018 | 4961 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2013 | 647 | 0.020 |
Why?
| Positron-Emission Tomography | 1 | 2010 | 285 | 0.020 |
Why?
| Membrane Proteins | 1 | 2015 | 1121 | 0.020 |
Why?
| Algorithms | 1 | 2015 | 1638 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 3380 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 2551 | 0.020 |
Why?
| Adolescent | 1 | 2024 | 20374 | 0.010 |
Why?
| Brain | 1 | 2014 | 2629 | 0.010 |
Why?
| Young Adult | 1 | 2014 | 12404 | 0.010 |
Why?
|
|
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|